Detailed explanation of standard usage and combination regimen of Tafasitamab

Tafasitamab (Tafasitamab) is an anti-CD19 monoclonal antibody, mainly administered by intravenous infusion. The standard dose is 12 mg/kg. The required dose should be accurately calculated based on the patient's weight before each dose. Pretreatment with an antihistamine and an antipyretic (e.g., acetaminophen) prior to administration is recommended to prevent infusion-related reactions. Within 3 weeks before treatment, it is recommended that patients undergo HBV screening and bone marrow function assessment to determine whether they are suitable for immunotherapy.

The currently recommended combination regimen isTafasitamab combined with lenalidomide (lenalidomide) to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who are not suitable for autologous stem cell transplantation. The combined use period of the two drugs is 3 cycles before the first phase (each cycle 28 days), Tafasitamab in the >13Dosing is as follows: Cycle 1 is 3 times per week (D1, D4, D8, D15, D22), No. 23The cycle is 2 times per week (D1 and D15). Lenalidomide is administered orally once a day. The recommended starting dose is 25mg. It should be taken continuously for 21 days and then discontinued for 7 days.

After completing 3 cycles of combination therapy, if the patient's disease is well controlled and well tolerated, he can enter the Tafasitamab single-drug maintenance phase. The dosing frequency during the maintenance phase is usually once every two weeks (Q2W) until the disease progresses or the patient is no longer able to tolerate treatment. During maintenance treatment, patients still need to regularly monitor blood routine, immune indicators and imaging examinations to dynamically evaluate efficacy and toxic reactions.

In actual clinical practice, doctors can make appropriate adjustments to the dosage and frequency based on the patient's drug resistance, previous treatment history, and complications. For some patients, combining rituximab (Rituximab) or considering the use of Tafasitamab as a bridge before subsequent CAR-T treatment has also become a research hotspot. In the future, with the advancement of research on more combination immunotherapy regimens, Tafasitamab is expected to play a wider role in initial treatment or maintenance treatment. Patients should fully communicate with professional hematologists before treatment to clarify the purpose of treatment and possible adjustment strategies.

Reference materials:https://www.fda.gov/drugs/